440 related articles for article (PubMed ID: 27986369)
1. Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma.
Bex A; Albiges L; Ljungberg B; Bensalah K; Dabestani S; Giles RH; Hofmann F; Hora M; Kuczyk MA; Lam TB; Marconi L; Merseburger AS; Staehler M; Volpe A; Powles T
Eur Urol; 2017 May; 71(5):719-722. PubMed ID: 27986369
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib as adjuvant therapy for renal cell carcinoma.
Baker H
Lancet Oncol; 2016 Nov; 17(11):e485. PubMed ID: 27773485
[No Abstract] [Full Text] [Related]
5. Mixed Results for Sunitinib in Renal Cancer.
Cancer Discov; 2017 Jan; 7(1):OF6. PubMed ID: 28062674
[TBL] [Abstract][Full Text] [Related]
6. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
7. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials.
Gyawali B; Ando Y
Ann Oncol; 2017 Apr; 28(4):898-899. PubMed ID: 27993814
[No Abstract] [Full Text] [Related]
9. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
[TBL] [Abstract][Full Text] [Related]
10. Current evidence and the evolving role of sunitinib in the management of renal cell carcinoma.
Noronha V; Joshi A; Bakshi G; Tongaonkar H; Prabhash K
Indian J Cancer; 2016; 53(1):102-8. PubMed ID: 27146754
[TBL] [Abstract][Full Text] [Related]
11. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma.
Lane BR; Derweesh IH; Kim HL; O'Malley R; Klink J; Ercole CE; Palazzi KL; Thomas AA; Rini BI; Campbell SC
Urol Oncol; 2015 Mar; 33(3):112.e15-21. PubMed ID: 25532471
[TBL] [Abstract][Full Text] [Related]
12. Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy.
Dall'Oglio MF; Sousa-Canavez JM; Tanno FY; Tiseo BC; Crippa A; Dos Reis ST; Leite KR; Srougi M
Int Braz J Urol; 2011; 37(2):180-5; discussion 185-6. PubMed ID: 21557834
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant treatment in renal cell carcinoma.
Dizman N; Adashek JJ; Hsu J; Bergerot PG; Bergerot CD; Pal SK
Clin Adv Hematol Oncol; 2018 Aug; 16(8):555-563. PubMed ID: 30148828
[TBL] [Abstract][Full Text] [Related]
14. [Advanced sarcomatoid renal cell carcinoma effectively treated with sunitinib: report of a case].
Tsuchiyama K; Ito H; Ishida H; Itoh H; Yokoyama O
Hinyokika Kiyo; 2011 Nov; 57(11):615-8. PubMed ID: 22166824
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.
Staehler M; Motzer RJ; George DJ; Pandha HS; Donskov F; Escudier B; Pantuck AJ; Patel A; DeAnnuntis L; Bhattacharyya H; Ramaswamy K; Zanotti G; Lin X; Lechuga M; Serfass L; Paty J; Ravaud A
Ann Oncol; 2018 Oct; 29(10):2098-2104. PubMed ID: 30412222
[TBL] [Abstract][Full Text] [Related]
16. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
Sakai I; Miyake H; Fujisawa M
BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
[TBL] [Abstract][Full Text] [Related]
17. [Neoadjuvant therapy for renal cancer].
Thibault F; Rixe O; Meric JB; Renard-Penna R; Boostan H; Mozer P; Comperat E; Richard F; Bitker MO
Prog Urol; 2008 Apr; 18(4):256-8. PubMed ID: 18501308
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of T4 renal cell carcinoma after a neoadjuvant targeted therapy using sunitinib: report of a case.
Ueda K; Noguchi M; Suekane S; Moriya F; Nagayoshi R; Ejima K; Momozono K; Matsuoka K
Kurume Med J; 2011; 58(3):95-8. PubMed ID: 22531125
[TBL] [Abstract][Full Text] [Related]
19. [A case of recurrent intracaval renal cell carcinoma effectively treated with sunitinib].
Komeya M; Matsumoto T; Fujinami K; Senga Y; Asakura T; Goto A
Hinyokika Kiyo; 2010 Sep; 56(9):499-503. PubMed ID: 20940524
[TBL] [Abstract][Full Text] [Related]
20. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
